FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC By Ogkologos - July 29, 2026 84 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Teclistamab ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated NSCLC MOST POPULAR EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients July 26, 2024 Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in... December 12, 2023 Cancer Survivors Face High Rates of Housing Insecurity February 5, 2022 Why haven’t we cured cancer? June 20, 2022 Load more HOT NEWS Expressive Writing, What is It? 3…2…1…Countdown to Medicare Open Enrollment EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab Tumors May Shed Protein to Create Barriers that Block Immune Cells
